ETERN Therapeutics, a Shanghai-based developer of small-molecule anti-tumor drugs, has announced the commencement of a Series B+ financing round. The initial phase of this funding round was co-led by the AZ-CICC Fund and another Wuxi-based fund, with participation from Wuxi Capital. The capital raised will be directed towards the construction of the LLPS protein liquid-liquid separation technology platform and the early development and clinical trials of their drug candidates.
ETERN Therapeutics prides itself on possessing the globally leading protein liquid-liquid separation technology platform, known as the LLPS platform. This platform integrates AI-enabled phase separation target discovery, high-throughput and high connotation drug screening, along with drug optimization technology. It offers a novel perspective and strategy for innovative drug development, particularly for drugs targeting “undruggable” targets, potentially revolutionizing the approach to developing therapies for previously intractable diseases.- Flcube.com
